Impact of Age and Comorbidity in Myelodysplastic Syndromes

Author： Stauder Reinhard   Nösslinger Thomas   Pfeilstöcker Michael   Sperr Wolfgang R.   Wimazal Friedrich   Krieger Otto   Valent Peter  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.6, Iss.9, 2008-10, pp. : 927-934

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 22, Iss. 16, 2016-05 ,pp. : 2349-2357

Bentham Science Publishers

Access to resources Recommend Favorite

Myelodysplastic Syndromes

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 9, 2008-10 ,pp. : 902-902

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 22, Iss. 16, 2016-05 ,pp. : 2333-2344

Bentham Science Publishers

Access to resources Recommend Favorite

Decitabine: In Myelodysplastic Syndromes

By McKeage Kate   Croom Katherine F.  

Drugs, Vol. 66, Iss. 7, 2006-01 ,pp. : 951-958

Adis International

Access to resources Recommend Favorite

Azacitidine: In Myelodysplastic Syndromes

By Siddiqui M. Asif A.   Scott Lesley J.  

Drugs, Vol. 65, Iss. 13, 2005-01 ,pp. : 1781-1789

Adis International

Access to resources Recommend Favorite